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Background: Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder
characterized by symptoms of inattention and impulsivity and/or hyperactivity and a range of cognitive
dysfunctions. Pharmacological treatment may be beneficial; however, many affected individuals continue to have
difficulties with cognitive functions despite medical treatment, and up to 30 % do not respond to pharmacological
treatment. Inadequate medical compliance and the long-term effects of treatment make it necessary to explore
nonpharmacological and supplementary treatments for ADHD. Treatment of cognitive dysfunctions may prove
particularly important because of the impact of these dysfunctions on the ability to cope with everyday life. Lately,
several trials have shown promising results for cognitive computer training, often referred to as cognitive training,
which focuses on particular parts of cognition, mostly on the working memory or attention but with poor
generalization of training on other cognitive functions and functional outcome. Children with ADHD have a
variety of cognitive dysfunctions, and it is important that cognitive training target multiple cognitive functions.
Methods/Design: This multicenter randomized clinical superiority trial aims to investigate the effect of “ACTIVATE™,” a
computer program designed to improve a range of cognitive skills and ADHD symptoms. A total of 122 children with
ADHD, aged 6 to 13 years, will be randomized to an intervention or a control group. The intervention group will be
asked to use ACTIVATE™ at home 40 minutes per day, 6 days per week for 8 weeks. Both intervention and control
group will receive treatment as usual. Outcome measures will assess cognitive functions, symptoms, and behavioral
and functional measures before and after the 8 weeks of training and in a 12- and 24-week follow-up.
Discussion: Results of this trial will provide useful information on the effectiveness of computer training focusing on
several cognitive functions. Cognitive training has the potential to reduce cognitive dysfunctions and to become a
new treatment option, which can promote a more normal neural development in young children with ADHD and thus
reduce cognitive dysfunctions and symptoms. This could help children with ADHD to perform better in everyday life
and school.
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ADHD is one of the most prevalent psychiatric disorders
in child and adolescent psychiatry, affecting approxi-
mately 5 % of school-aged children and adolescents [1–
3]. ADHD is associated with poor academic perform-
ance, poor social functioning [4, 5], increased risk of
drug abuse [6, 7], psychotic disorders [8, 9] and crimin-
ality [10, 11], as well as increased mortality [12]. The eti-
ology of ADHD is still unknown, but there is evidence for
a complex interaction between multiple genes and environ-
mental factors [13]. Empirical studies have shown struc-
tural and functional abnormalities in the brain of
individuals with ADHD [14, 15]. Additionally, the brain in
children with ADHD is characterized by a cortical matur-
ation delay in terms of the reaching the peak cortical thick-
ness [16].
A wide range of cognitive functions is affected in ADHD,
yet a specific ADHD cognitive profile has not been identi-
fied [17]. The cognitive impairments are very heterogenic
in severity and the affected areas. Spatial working memory,
impulse inhibition and vigilance are found to be the most
impaired functions according to two large meta-analyses of
observational studies comparing cognitive functions in
patients with ADHD with healthy participants [18, 19].
Functions like inhibitory control, selective and sustained
attention, attention switching and processing speed are
also significantly impaired [16, 20–22]. These features are
associated with the executive control system [23–26] and
are often manifest in early childhood and persistent over
time [11, 27]. Executive dysfunctions are often seen in
individuals with ADHD. Children with ADHD display
significant impairment in executive functions compared
to typically developing controls as a group, but only 50 %
of the patients exhibit executive dysfunctions at the indi-
vidual level [28].
Although there is some evidence supporting the benefi-
cial effects of stimulant medication for ADHD [29], the
treatment is not a cure as the symptoms return immedi-
ately after treatment discontinuation. Furthermore, 20 %
to 30 % of individuals with ADHD do not show a positive
response to stimulant medications, and long-term effects
are variable [30–32].
Cognitive training
Cognitive training is rooted in cognitive rehabilitation,
based on the concept that direct training can result in a
reorganization of neural functions. Among other effects,
neuroplasticity allows the central nervous system to
learn new skills, remember information and reorganize
neural networks in response to external stimulation [33].
The basic mechanisms involved are neurogenesis, pro-
grammed cell death and activity-dependent synaptic plas-
ticity [33]. Childhood is a period of changes in the brain’s
anatomical structure and synaptic connections. A child’sbrain is more susceptible to the environmental impact
than the adult’s brain due to increased plasticity [33].
Thus, injuries and some neurological diseases are over-
come by children faster and easier than by adults. Several
studies indicate that the peak of brain plasticity is reached
within the first 7 years of life [34], although the potential
is likely to be lifelong. For example, a functional magnetic
resonance imaging (fMRI) open trial of young healthy
adults found that training working memory resulted in an
increased brain activity in the dorsolateral, prefrontal, and
parietal association cortex, indicating plasticity of the
neural system [35]. These cortical areas are overlapping
the prefrontal regions, which are likely implicated in the
pathology of ADHD [36, 37]. Despite the hypothesis that
children under the age of 7 have better neuroplasticity
and therefore may benefit more from cognitive training as
compared to older children, we have not identified any
studies investigating the effect of cognitive training in dif-
ferent age groups.
Cognitive training is typically delivered in a computerized
format and is aimed at training cognitive functions that are
deficient in a patient population by using a special kind of
computer games. A rapidly growing number of randomized
trials support the hypothesis that cognitive dysfunctions
can be trained in children with ADHD [38–41]. Most
ADHD trials with children have focused solely on working
memory training and findings have been somewhat incon-
sistent [42–44]. Overall, working memory training shows
effects on verbal and spatial working memory [45], and
these effects are generalized to improved sustained atten-
tion up to 6 months follow-up [42]. Some few studies have
shown improvements in academic abilities, but there is no
consensus yet as several newer studies had negative results
[46–48]. Working memory, combined with response inhib-
ition training, has shown significant improvements on
symptoms, spatial working memory, ability to ignore dis-
tracting stimuli and sustained attention as rated by a signifi-
cant other [41]. Training of executive functions improved
parent-rated executive functions and ADHD behavior when
compared to waiting-list condition [49].
Fewer trials have focused on the attention training
in children with ADHD that results in a significant
improvement in trained and untrained attention and
vigilance [39, 50–52], a measure of school perform-
ance and a significant reduction in parent and teacher
observation of inattention [39, 40, 53]. In addition, the
effects on inhibition and working memory have been
found [52], and significant changes in inattentiveness,
behavior and executive functions measured by parent
ratings on Behavior Rating Inventory of Executive
Functions (BRIEF) [54].
Structural and functional correlates of cognitive train-
ing have been shown in several small studies. Enhanced
activity in neural structures closely related to ADHD
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in bilateral middle frontal cortex and right inferior-
posterior cerebellum after attention and executive func-
tions training [56]. Cognitive training has also been
shown to induce neurochemical changes at the synapse
in dopamine function after training [57].
In conclusion, randomized trials and observational
studies suggest that cognitive training of children with
ADHD has some beneficial effects. However, the em-
pirical evidence in this field is still insufficient as most
trials have a high risk of systematic errors (bias) mainly
due to lack of blinding, incomplete outcome data, and
selective outcome reporting. Further, most trials have
small sample sizes, which result in an increased risk of
imprecision. As children with ADHD have impairments
in many different cognitive functions, there is a need for
randomized trials to examine effects of broader cognitive
training, rather than focusing on only one or two domains,
for instance, working memory, response inhibition or sus-
tained attention. It is important to validate and extend
existing knowledge on the effects of cognitive training for
patients with ADHD.
Hence, to overcome some of these limitations, the
present trial will use ACTIVATE™ a cognitive computerized
program that aims to improve eight different cognitive
functions. We will include a sample of children and adoles-
cents with ADHD, and in addition to considering the rat-
ings of clinical symptoms by parents and teachers, we will
measure the outcome with an objective, valid and reliable
cognitive test battery. The trial is, to our knowledge, the
first to examine the effect of cognitive training on the out-
come of Cambridge Automated Neurocognitive Test Bat-
tery (CANTAB) in children with ADHD.
Methods/Design
Objectives
The primary objective is to investigate whether computer
training with the games embedded in ACTIVATE™
(http://denmarkstudy2.c8sciences.com/?language=da) has
a positive effect on specific cognitive functions. The sec-
ondary objectives are to investigate whether there is an
effect on ADHD symptoms and functional outcome.
Exploratory objectives are to investigate the effects at
12 and 24 weeks after training and to investigate
whether younger children benefit more from training
than older children.
Trial sites
Participants are included in three sites in southern
Denmark: the Child Psychiatric Departments of Aabenraa
(including Augustenborg), Kolding and Odense.
The three sites are part of the same organization, Region
of Southern Denmark, and are under the same leadership.
All children and adolescent mental health hospitals inDenmark are state-owned, and everyone is eligible to get
treatment. Referral from the treating physician or school
psychologists is required. No children who are being
treated by private practicing child and adolescent psychia-
trists will be included in the study. One site (Odense) is part
of a university hospital, and the two other sites are part of
regional hospitals. Eventual differences between sites will be
assessed using data on demographics.
Enrollment of children into the trial is done consecutively
throughout the calendar year. The vast majority of children
will be enrolled during school year. A few participants will
be enrolled during school vacations, but as the intervention
is home-based, this will likely not affect the adherence.
Assessments of eligibility
All children who are newly referred with ADHD symptoms
to one of the Child Psychiatric Departments or currently in
treatment with ADHD-medication will be invited to partici-
pate in the trial and will be offered an individual informa-
tion session, after which their custodian can give their
informed consent. The diagnostic assessment is done in a
two-step model: In Step 1 parents, a teacher and children
over 11 years of age complete an online questionnaire,
including the Strength and Difficulties Questionnaire
(SDQ) [58, 59] in conjunction with the psychiatric diagnos-
tic interview Development and Well-being Assessment
(DAWBA). The DAWBA is a valid hybrid between a struc-
tured and a semi-structured interview for the diagnosis of
child and adolescent psychiatric disorders according to
both the ICD-10 and DSM-IV [60, 61]. DAWBA’s sensitiv-
ity is 92 % in a clinical sample and its specificity is 89 % for
all psychiatric diagnoses in a community sample [60]. Par-
ents and teachers answer structured and open-ended ques-
tions regarding diagnostic symptoms using the online
DAWBA-platform. A child and adolescent psychiatrist rates
this information clinically. Children fulfilling diagnostic cri-
teria for ADHD based on this rating of DAWBA proceed
to Step 2, which includes a confirmatory clinical interview
with parents at the hospital, using the Kiddie-Schedule for
Affective Disorders and Schizophrenia (K-SADS, ADHD
section) [62]. K-SADS is a semi-structured clinical interview
of parents and children and is the most widely used psy-
chometric instrument for the diagnostic investigation of
children in clinical research. All children with confirmed
ADHD are assessed with Reynolds Intellectual Assessment
Scales (RIAS) [63] to ensure that all participants have an IQ
above 80. Finally, children are included in the trial if they
comply with the following inclusion and exclusion criteria.
Inclusion criteria
Children are included if the following inclusion criteria
are fulfilled: ADHD diagnosis after DAWBA interview
[60] and verification with clinical interview K-SADS,
ADHD section parent interview [62]; age between 6 and
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puter and the internet; and informed consent.
Exclusion criteria
Patients fulfilling any of the following exclusion criteria
will not be included: comorbid conduct disorder, autism
spectrum disorder, depression or schizophrenia; head
injury or verified neurological disease; intelligence quo-
tient (IQ) < 80; motor or perceptual handicaps that pre-
vent computer use; medical condition that requires
primary treatment, and no informed consent from cus-
todian (Fig. 1).
Interventions
Both the intervention group and the control group
will receive treatment as usual (TAU). TAU consists
of clinical assessment and treatment. Clinical assess-
ment includes intelligence tests, cognitive testing,
school observations and parent and teacher question-
naires. TAU may involve psycho-education, parentAssess f
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“Catch the ball,” “Butterflies,” and “What comes next.”
These are described below.
1. Catch the ball: In this game, there is a ball moving
across the computer screen. The child has to use the
computer mouse to chase the ball with the arrow on
the screen. Every time the ball turns red, the child
should put the arrow on the ball, click the mouse,
and thus, catch the ball. Every time a child catches a
ball, the computer makes a nice sound, and the
child gets points. If the child waits too long to click
or clicks outside of the ball, s/he will miss the ball,
and the computer will make a different sound. The
child has to watch the ball all the time and get as
many points as possible. When many balls have
been caught, the speed will increase. If the child
misses some balls, then they will begin to move
more slowly, and it will be easier to catch them. The
target - red balls or blue balls - will keep changing.
The rule is disclosed by looking at the ball on the
top of the screen. In the beginning, the child has to
catch only the red or blue balls. As the child
progresses to higher levels of the game, the rules
will begin to change: Initially, the child has to
catch a ball when it is the same color as the
previous one. Later, the child has to catch a ball
if it is a different color than the previous one.
Then, two balls bounce across the screen at the
same time and have to be watched simultaneously, as
all of the rules described before now apply to both
balls. Later, three balls - red, blue and green - are
introduced, and the child has to catch the blue and
red, but never the green balls. “Catch the ball”
engages different cognitive functions at the same
time: sustained attention, response inhibition and
cognitive flexibility. The load on these cognitive
functions is increasing during the game and
working memory and multiple simultaneous
attention are trained at the higher levels of the
game.
2. Butterflies: In this game, there are butterflies flying
across the screen. Each one carries a sign with a
number, a word or a picture on it. The child uses
the computer mouse to click on all the signs that
have a number or the name of a number. Sometimes
the number is spelled out in letters like “t” “w” “o”
for 2. These are the targets to look for and click on
before the butterfly carries them all the way across
the screen. If a child clicks on the wrong butterfly, it
falls to the ground. As the child progresses to higher
levels, the rules keep changing. The child has to look
for signs with letters of the alphabet, animals, plants,
furniture and things to take on a vacation. Later, thetargets are different kinds of plants with an
exception, such as flowers. As the game progresses,
the targets change to two different categories, for
example, the child has first to click on a picture of
food, after that on a picture of clothing, and to
continue to go back and forth between the two. This
game is mainly engaging the conceptualization of
categories and sustained attention on all levels. Some
levels also make demands on response inhibition and
cognitive flexibility.
3. What comes next: This game trains mainly pattern
recognition and, on some higher levels, cognitive
flexibility and the use of categories. The child sees
some pictures, numbers or shapes in a row that
make a pattern or sequence. There is an empty
space in the top row. There are some other
pictures, numbers or shapes in another set of
boxes in a second row below the first. The task is
to click on the thing in the second row that goes
best in the empty space in the first row, and fits
with the pattern on the first row. On the upper
right-hand side of the screen, the time allowed to
make a choice is displayed. When a child gets
questions right, the time remaining to answer the
next questions is shortened. Three seconds is the
shortest time given to provide an answer. The
child graduates and moves on to new levels of
the program when enough questions have been
answered correctly with only 3 seconds for each
question. When a child has worked hard on a
level for a long enough time, the computer will
move to the next level even if the child was not
able to answer the questions within the 3 seconds.
The faster the child works, the more points s/he
can earn.
In all three games, the child is earning points, which
are converted into coins. At the end of all three games,
the child comes to a “garden” where s/he can purchase
different things. The child can decide to buy things for
the garden, such as plants and animals, or a car, a zoo or
a house. The child can buy things after each game or
can save coins to buy more expensive things later. The
games are designed in a manner to be interesting and re-
warding for children. All participants are doing the same
kind of exercises. All participants start at the same very
basic level. Progression and the level of difficulty in the
games depend on the child’s performance. Hence, the
level of difficulty is therefore dynamically adjusted dur-
ing the trial, according to the abilities of each child or
cognitive phenotype.
Training with ACTIVATE™ is home-based for 40 mi-
nutes per day, 6 days per week, for 8 weeks, resulting
in a cumulative training of a maximum of 32 hours.
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on and is measuring compliance, time on task and
progress. All participants randomized to the interven-
tion group are introduced to the program at the
clinic. In case of any problems with the program, the
participants can contact the principal investigator. C8
is also providing IT support. Parents are given verbal
and written instructions that the child should use a
computer with an external mouse (not an iPad or a
laptop with an integrated mousepad), that training
should be performed in a quiet setting, and that using
headphones is mandatory. In addition, the parent are
instructed to help the child remember and engage in
training and to supervise the child during training
sessions, to ensure adherence. We are in touch with
parents, and they can contact us any time. Parents
are given the instruction to supervise the child and
make sure they are doing the training. There were no
restrictions on the time of the day the training should
be performed. However, we inform parents that most
children usually like to do the exercises in the late
afternoon or early evening and that parents should
ensure that sessions do not conflict with school or
family schedules.
Control group
The control group will only receive treatment as usual.
Randomization
Randomization is performed centrally by the Copenhagen
Trial Unit. Participants are randomized 1:1 to the
intervention group or control group. The allocation
sequence is computer-generated with a varying block
size kept unknown to the investigators, and it is
stratified by trial site (“Aabenraa,” “Kolding,” or
“Odense”) and use of medication (“yes” or “no”). Allo-
cation is performed by the investigator telephoning
the Copenhagen Trial Unit, giving a personal PIN
code as well as information about the participant
(strata, participant ID number etc.), and the partici-
pant is then allocated to an intervention group.
To examine whether the randomization sufficiently re-
duced the risk of systematic group differences between
children in the intervention and the control arm, we will
compare the distribution of history of scholar retention
events, and pharmacological treatment (dose and type of
medication) in the child, mean parental age, socioeco-
nomic status and level of education, and the number of
people living at home.
Blinding
Due to the nature of the trial, it is not possible to blind
the participants and their parents. However, we will em-
ploy blinding in all other possible areas. Investigatorsconducting the cognitive testing with CANTAB will be
blind to the participants’ group allocation. The statistical
analyses will be performed blinded with the two inter-
vention groups coded as, for example, X and Y. The
analyses will be presented blinded to the Steering
Committee, who will draw two conclusions: one assum-
ing that X is the intervention group and Y is the control
group, and one assuming the opposite. After this, the
blind will be broken.
To reduce the risk of biasing the rating of outcomes
caused by unblinding information on group allocation,
we chose an objective computerized primary outcome
measure on the CANTAB. Still, the clinicians perform-
ing the CANTAB are blinded to group allocation. The
treating physicians are not directly connected to the trial
and do not assess or provide information on any trial
outcomes. Due to regulations by the ethics committee,
we were not allowed to inform the treating physician
about included children to avoid that influencing the
treatment in the outpatient clinic. Hence, as these clini-
cians were responsible for the treatment as usual (TAU)
in both groups, they were also blinded to the group allo-
cation of the child to ensure that this did not affect the
TAU.
Outcomes
For an overview of all outcomes and assessments, please
see Table 1.
Each CANTAB assessment lasts between 70 and 90 mi-
nutes. We aim to collect all cognitive assessments be-
tween 8:30 am and 2:00 pm to avoid a time of the day
that would have an impact on the cognitive perform-
ance. While the child is being assessed, the parent ques-
tionnaire data are collected. If the child is unable to
complete the assessment in one session, the assessment
can be split up.
Primary outcome
CANTAB is a nonverbal computerized cognitive test
battery with solid psychometric properties [64–66]
(Cambridge Cognition Limited, 2011). The primary
outcome is the sustained attention test from the
CANTAB: “Rapid Visual Information Processing
(RVP) probability of hit,” assessed at the end of the
intervention.
Secondary outcomes
The following secondary outcomes will be assessed at
the end of the intervention:
1. Parent-rated ADHD symptoms assessed by ADHD-
Rating Scale (ADHD-RS) (parent edition) [67].
2. Teacher-rated ADHD symptoms assessed by
ADHD-RS (teacher edition) [67].
Table 1 Outcomes and time points for assessment in the trial. Specification of all outcome measures at each time point in the trial
Legend:
aDevelopment and Well-being Assessment (DAWBA); bKiddie-Schedule for Affective Disorders and Schizophrenia (K-SADS); cReynolds Intellectual Assessment
Scales (RIAS); dCambridge Automated Neurocognitive Test Battery (CANTAB); eRapid Visual Information Processing (RVP); fAttention Attention Deficit Hyperactivity
Disorder-Rating Scale (ADHD-RS); gBehavior Rating Inventory of Executive Functions (BRIEF); hSwitching Task (AST); iMatch to Sample (MTS); jChoice Reaction Time
(CRT); kStop Signal Task (SST); lSpatial Working Memory (SWM); mStockings of Cambridge (SOC); nIntra-Extra Dimensional Set Shift (IED); oPaired Associates Learning
(PAL); pWeis’s scale of disability-Parent Report (WFIRS-P)
Each CANTAB assessment lasts between 70 and 90 minutes and is collected between 8:30 am and 2:00 pm. While the child is assessed, questionnaire data from
the parents are collected. If the child is unable to complete the assessment in one session, the assessment can be split up
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Inventory of Executive Functions (BRIEF) (parent
edition) [68].
4. Teacher-rated behavior assessed by BRIEF (teacher-
edition) [68].
Exploratory outcomes
The following exploratory outcomes will be assessed at
the end of the intervention:
1. CANTAB Attention Switching Task (AST).
2. CANTAB Match to Sample (MTS).
3. CANTAB Choice Reaction Time (CRT).
4. CANTAB Stop Signal Task (SST).
5. CANTAB Spatial Working Memory (SWM).
6. CANTAB Stockings of Cambridge (SOC).
7. CANTAB Intra-Extra Dimensional Set Shift (IED).
8. CANTAB Paired Associates Learning (PAL).
9. CANTAB RVP Probability of False Alarms.
10. CANTAB RVP Reaction Latency S.D.11. BRIEF (Inhibit) (parent-rated).
12. BRIEF (Shift) (parent-rated).
13. BRIEF (Emotional Control) (parent-rated).
14. BRIEF (Initiate) (parent-rated).
15. BRIEF (Working Memory) (parent-rated).
16. BRIEF (Plan/Organize) (parent-rated).
17. BRIEF (Organization of Materials) (parent-rated).
18. BRIEF (Monitor) (parent-rated).
19. BRIEF (Inhibit) (teacher-rated).
20. BRIEF (Shift) (teacher-rated).
21. BRIEF (Emotional Control) (teacher-rated).
22. BRIEF (Initiate) (teacher-rated).
23. BRIEF (Working Memory) (teacher-rated).
24. BRIEF (Plan/Organize) (teacher-rated).
25. BRIEF (Organization of Materials) (teacher-rated).
26. BRIEF (Monitor) (teacher-rated).
27. Weis’s scale of disability-Parent Report (WFIRS-P)
(Weis et al., 2005).
28. Non-serious adverse events.
29. Serious adverse events.
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24 weeks after the end of the intervention (Fig. 2).
Ethical issues
This trial is being conducted in accordance with the
protocol approved by the Danish Data Protection
Agency (ID.nr. 2008-58-0035) and the Regional Scientific
Ethical Committees for Southern Denmark (nr.
S20120096). The protocol is in accordance with the
latest version of the Declaration of Helsinki. No sig-
nificant deviation from the protocol will be imple-
mented without prior review and approval by the
regulatory authorities unless it may be necessary to
eliminate an immediate hazard to the trial partici-
pants. In this case, the deviation will be reported to
the regulatory authorities as quickly as possible.
A child can participate in the trial if the written con-
sent of both parents is obtained. The patients’ treatment
as usual will not be affected, including the use of medi-
cations, by their participation in this trial. When testing
with CANTAB, patients will be asked to postpone any
ADHD medication for 24 hours before testing, when
medical treatment can affect efficacy measures. Trial
participants will receive a gift certificate worth DKK
400 for participation. Transportation costs will be
reimbursed.
The processing of personal data will be respected.
There are no known risks associated with the use of
computerized cognitive training. The method has
been tested in many studies with patients with schizo-
phrenia (see reviews [69, 70]) and in children with
ADHD [38–40, 53]. No adverse events have been
reported.
Discontinuation and withdrawal
Although parents may have agreed to participate, they
can always withdraw their child from the trial withoutTimeline
Fig. 2 Timeline of the study enrollment. Timeline of participant assessments
Development and Well-being Assessment; 3) K-SADS, Kiddie-Schedule for A
Assessment Scales; 5) CANTAB, Cambridge Automated Neurocognitive Test
Scale; 7) BRIEF, Behavior Rating Inventory of Executive Functions; 8) WFIRS-Pfurther explanation. Pulling a child out of the trial, will
not affects his or her further treatment. Patients can
choose to stop at any time in the trial. Patients who were
randomized will be included in the intention-to treat
analyses unless they completely withdraw consent. In
this case, all data regarding this participant will be
deleted.
Statistical plan and data analysis
Sample size
We are planning a trial of a continuous response vari-
able, “CANTAB RVP probability of hit,” from an inde-
pendent control, and experimental participants will be
allocated at a 1:1 ratio. In a pilot project (Bikic et al., un-
published data), adolescents with ADHD played a set of
games from Scientific Brain Management for 7 weeks.
Here, the “CANTAB RVP probability of hit” was nor-
mally distributed, with a standard deviation (SD) of 0.22
points. If the true difference in the experimental and
control mean is 0.13 points, we will need to include 61
experimental participants and 61 control participants to
be able to reject the null hypothesis that the population
means of the experimental and control groups are equal
with a probability (power) of 90 %. The type I error
probability associated with this test of this null hypoth-
esis is 5 %. We will thus include 122 participants in
total.
Power
Assuming the minimal relevant difference is 0.5 SD for
all the secondary outcomes and the significance level of
the various tests of Hommel’s procedure is within the
range of alpha = 0.05 and 0.05/4 = 0.0125 and the sample
size is 122, the power of the individual tests will range
between 59 % and 78 % (Table 2). A power of 78 % is
judged to be reasonable, whereas a power of 59 % is
insufficient.in the trial. 1) SDQ, Strength and Difficulties Questionnaire; 2) DAWBA,
ffective Disorders and Schizophrenia; 4) RIAS, Reynolds Intellectual
Battery; 6) ADHD-RS, Attention Deficit Hyperactivity Disorder-Rating
, Weis’s scale of disability-Parent Report; and 9) TAU, treatment as usual
Table 2 Power estimations for the secondary outcome measures ADHD-RS and BRIEF
Outcome Minimal relevant difference SDa Sample size Power assuming an
alpha of 1.25 %
Power assuming an
alpha of 5 %
ADHD-RSb (parents-assessed) 5 points 10 points 122 59 % 78 %
ADHD-RS (teacher-assessed) 5 points 10 points 122 59 % 78 %
BRIEFc (parents-assessed) 0.25 points 0.5 points 122 59 % 78 %
BRIEF (teacher-assessed) 0.25 points 0.5 points 122 59 % 78 %
Legend:
aSD, standard deviation
bADHD-RS, attention deficit hyperactivity disorder rating scale. Minimal relevant difference and SD calculated from a previous pilot project
(Bikic et al. unpublished data)
cBRIEF, Behavior Rating Inventory of Executive Functions. Minimal relevant difference and SD calculated from the BRIEF professional manual [68]
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For all outcomes, we will present the test statistic and
the corresponding P values for exploratory purposes.
The purpose of the analysis of the secondary outcomes
is to make additional claims of treatment benefits in
addition to those already established by the analysis of
the primary outcome. Consequently, multiplicity adjust-
ments are needed. Multiplicity adjustments generally re-
quire a strong control of the familywise error rate. With
regard to this, a useful approach is the gatekeeping ap-
proach [71], which we will apply in this trial.
There is one primary and four secondary outcomes.
Thus, the primary outcome will be the gatekeeper of the
family of secondary outcomes. The sample size has been
estimated using a risk of type I error (alpha) of 0.05. The
primary outcome will consequently be analyzed and
interpreted according to a two-sided significance level of
P ≤ 0.05. Thus, if P of the test of the primary outcome
is ≤ 0.05, the primary outcome is assessed as statistically
significant. In this case, we will use Hommel’s procedure,
which is uniformly more powerful than the Holm as well
as the Hochberg adjustment procedures. This means
that the alpha of 0.05 can be transferred to the sec-
ondary outcomes that will be tested in a pre-specified
sequence at the 0.05 level of significance (see se-
quence in Table 2). The approach requires that as
soon as the P value of a test is > 0.05, the null hy-
potheses of the remaining secondary outcomes are ac-
cepted regardless of the test statistics.
If P of the test of the primary outcome is > 0.05, the
primary outcome is assessed as statistically insignificant.
Consequently, the trial result is insignificant, and all the
null hypotheses of the four secondary outcomes will be
accepted regardless of the test statistic.
All exploratory outcomes and exploratory analyses
of the primary and secondary outcomes will likewise
be subject to statistical tests. However, if P of the test
is ≤ 0.05, the outcome will not be assessed as statisti-
cally significant due to multiplicity and the increased
risk of a type I error. Likewise, if P > 0.05, we cannot
assess the outcome as statistically insignificant due toa potential lack of power. All exploratory analyses will
thus be strictly hypothesis generating.
Analytical model
For the analysis of the continuous outcomes, structural
equation models (for example, “proc calis” in SAS 9.3)
including the direct maximum likelihood method (full
information likelihood) will be used (see section on
missing values). If the assumptions of a regression ana-
lysis are not fulfilled, a non-parametric test will be used
(van Elteren’s test with stratification by one variable
“center”). For dichotomous outcomes, we will use logis-
tic regression to compare the results in the two groups.
Adjustments
All analyses will be adjusted for the stratification vari-
ables (“center” and “pharmaceutical treatment at base-
line”), and the outcome variable value will be assessed at
baseline.
Missing values
In the analysis of the continuous variables, structural
equation models (for example, “proc calis” in SAS 9.3)
that include the direct maximum likelihood method (full
information likelihood) will be used. Applying this
method implies that unbiased estimates of the regression
parameters will be obtained as long as the values are
only missing at random. To improve the efficiency, all
auxiliary variables present among the outcomes will be
added to the model. An auxiliary variable is defined
as a variable not in the analytical model but corre-
lated (defined as |r| > 0.40) with one or more vari-
ables that 1) have missing values, and 2) are included
in the analytical model. Thus, the auxiliary variables
included may vary from one regression equation to
the next one.
Sensitivity analyses
Best-worst and worst-best sensitivity analyses of the pri-
mary outcome will be done. Here, missing values in one
intervention group are imputed by the minimum value
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values in the other group are imputed by the maximum
value found in the total material (“worst case”) and vice
versa. The range of the estimates of the two regression
parameters of the intervention indicator will convey an
impression of the bias one may expect if values are miss-
ing not at random.
Per-protocol analyses
For the primary and secondary outcomes, we will use
exploratory analyses to perform per-protocol analyses.
Participants will be included in the intervention group, if
they have complied with at least 20 out of the 48 sched-
uled computer training sessions. Participants will be in-
cluded in the control group if they have not attended
any computer training sessions.
Subgroup analyses
For the primary and secondary outcomes, we will per-
form subgroup analyses according to age. We will divide
the participants into two age groups of children aged 6
to 9 years or 10 to 13 years. We will perform a test of
interaction to assess whether the effect of the interven-
tion is different among the younger children compared
with the older children. If P of the test of interaction
is ≤ 0.05, we will present separate estimates for the
two subgroups. As the randomization procedure was
not stratified by age and we most likely will have re-
duced power for this analysis, the result is exploratory
and strictly hypothesis generating.
Sequential analysis
As the recruitment in the trial until present has been
slower than anticipated, we may face a scenario where we
have to end recruitment before the sample size of 122 par-
ticipants has been met. In this case, we plan to perform
sequential analysis to assess the results of significance test-
ing, taking sparse data and into consideration [72]. We
will for the primary outcome, CANTAB-RVP, use a min-
imal clinically relevant difference of 0.13 and a variance of
0.0484 (corresponding to a SD of 0.22). For the secondary
outcomes, we will use minimally relevant differences
of 5 points and a variance of 100 (corresponding to a
SD of 10 points) for both AHDH-RS assessments and
a minimal clinical relevance of 0.25 points and vari-
ance of 0.25 (corresponding to a SD of 0.5 points) for
both BRIEF assessments. For all outcomes, we will
use a type I error of 5 %, and a type II error of 10 %.
We will use the trial sequential analysis program for these
analyses (http://ctu.dk/tsa/) [73–76].
Discussion of clinical relevance
If the trial results indicate that this intervention reduces
specific cognitive deficits in children with ADHDwithout causing any adverse reactions effects, our inter-
pretation will be that the intervention can be an import-
ant part of a treatment plan as cognitive dysfunctions
are very common in children with ADHD. Furthermore,
if we find improvement in the BRIEF measures and
ADHD-RS, this would suggest that the effects of the
intervention could be generalized to behavior in an
everyday setting.
Monitoring of patient compliance issues
The intervention group compliance will be monitored
via the computer program that records patients log on,
which games they have played, and for how long.
Financial support
Aida Bikic is the initiator of the trial and the investigator
psychologist, research coordinator and PhD student.
Participants are being randomized in the Child and
Adolescent Psychiatric setting of Augustenborg and
Aabenraa, Odense and Kolding. The trial has received
grants from Region of Southern Denmark Psychiatry
Research, The Region of Southern Denmark’s PhD pool,
Child and Adolescent Psychiatric Department Aabenraa,
TrygFonden (J.nr. 7-12-1137) and the University of
Southern Denmark. C8 Sciences allowed us to use the
ACTIVATE™ program at no charge in this trial. None of
the funders has any role in the development of the trial
design, trial conduct or trial reporting.
Discussion
This trial is a multicenter, randomized clinical superior-
ity trial investigating the effect of a home-based 8-week
intervention for children with ADHD, using a com-
puterized cognitive training program, ACTIVATE™.
ACTIVATE™ was designed to enhance a broad range
of cognitive functions. The trial has several strengths:
it is conducted with adequate generation of allocation
sequence; adequate allocation concealment; adequate
blinding wherever possible; adequate reporting of all
relevant outcomes; adequate handling of incomplete
outcome data; and has no for-profit bias [77–80]. The
trial results will offer new and valuable contributions
to the field of cognitive training in children with
ADHD.
The trial also has some limitations. Due to the nature
of the trial, it is not possible to blind the participants,
their parents, or their teachers. A “sham” intervention
for the control group was considered. However, in order
to introduce an active control intervention that would
function as a true placebo, we needed to be sure that
this intervention had no beneficial or harmful effects,
which is difficult to document. Furthermore, a placebo-
training program would be somewhat boring in order to
have no training effect. This would potentially cause
Bikic et al. Trials  (2015) 16:480 Page 11 of 13problems with low adherence in the control group
and reveal group allocation. We consequently chose a
“treatment as usual” control group, thereby accepting
the risk of bias regarding the blinding that this
entails.
We included both drug-naïve children and children re-
ceiving pharmaceutical therapy in the trial. As the
randomization procedure is stratified for this variable, it
is not expected to influence the trial results. Further-
more, all children are required to be free of medication
24 hours before cognitive testing in order to influence
the results as little as possible. All patients are required
to perform cognitive assessments at four time points
without medication. This may present a potential threat
of bias in terms that patients, who are not able to func-
tion without medication for 24 hours prior to the test-
ing, could choose not to participate in the study. In this
case, some of the more severe cases with ADHD might
not be represented in the study sample. Overall, inclu-
sion of children regardless of pharmaceutical treatment
status is expected to increase the external validity of the
trial results.
We do not consider dropout of medical treatment dur-
ing the trial a threatening issue. In Denmark, ADHD
assessments, diagnostic procedures and initiation of
ADHD-medications is restricted to specialists of child
and adolescent psychiatry, and general practitioners are
not allowed to initiate this treatment [81, 82]. This result
in a lower prevalence of children and adolescents treated
with ADHD-medications (prevalence in 2010 was only
1.5 % [83], compared to most other Europeans countries
and certainly to most parts of the USA, and probably to
a less negative public attitude toward medication. Adher-
ence to medication in Denmark is likely higher than in
many other countries. The study protocol requires medi-
cated children to stay on medication during the inter-
vention period. Parents are encouraged to continue the
children’s medication, if they are on it at time of
inclusion.Trial status
The first participant was included and randomized in
March 2013. Recruitment is currently ongoing.
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